Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470

Nature Medicine

Volumn 10, Issue 3, 2004, Pages 255-261

  Satchi Fainaro, Ronit ^a   Puder, Mark ^a   Davies, John W ^b   Tran, Hai T ^c   Sampson, David A ^a   Greene, Arin K ^a   Corfas, Gabriel ^d   Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Polymer Laboratories Ltd   (United Kingdom)

^c UNIVERSITY OF TEXAS   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DRUG CARRIER; FUMAGILLOL CHLOROACETYLCARBAMATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; ANTINEOPLASTIC AGENT; CYCLOHEXANE DERIVATIVE; HYDROXYPROPYL METHACRYLATE; METHACRYLIC ACID DERIVATIVE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; POLYMER; SESQUITERPENE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG HALF LIFE; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LIVER REGENERATION; MELANOMA CELL; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CARCINOMA; CHEMICAL STRUCTURE; CHEMISTRY; CHICK EMBRYO; LIVER; LUNG TUMOR; MALE; MELANOMA; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REGENERATION;

ANIMALIA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CARCINOMA; CHICK EMBRYO; CYCLOHEXANES; ENDOTHELIAL CELLS; HUMANS; LIVER; LUNG NEOPLASMS; MALE; MELANOMA; METHACRYLATES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; POLYMERS; REGENERATION; SESQUITERPENES;

EID: 2342586114     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1002     Document Type: Article

References (49)

1. Folkman, J. Angiogenesis. in Harrison's Textbook of Internal Medicine 15th ed. (eds. Braunwald, E. et al.) 517-530 (McGraw Hill, New York, 2001).
2. Volpert, O.V. et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2, 473-483 (2002).
3. Ingber, D. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557 (1990).
4. Antoine, N. et al. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res. 54, 2073-2076 (1994).
5. Folkman, J. & Kalluri, R. Tumor angiogenesis. in Cancer Medicine (eds. Kufe, D.W. et al.) 161-194 (B.C. Decker, Hamilton, Ontario, 2003).
6. Folkman, J. Tumor angiogenesis. in Accomplishments in Cancer Research (eds. Wells, S.J. & Sharp, P.) 32-44 (Lippincott Williams & Wilkins, New York, 1998).
7. Kudelka, A.P., Verschraegen, C.F. & Loyer, E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N. Engl. J. Med. 338, 991-992 (1998).
8. Kudelka, A.P. et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. 3, 1501-1505 (1997).
9. Bhargava, P. et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5, 1989-1995 (1999).
10. Herbst, R.S. et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol. 20, 4440-4447 (2002).
11. Kim, E.S. & Herbst, R.S. Angiogenesis inhibitors in lung cancer. Curr. Oncol. Rep. 4, 325-333 (2002).
12. Stadler, W.M. et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17, 2541-2545 (1999).
13. Logothetis, C.J. et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 7, 1198-1203 (2001).
14. Rupnick, M.A. et al. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA 99, 10730-10735 (2002).
15. Schoof, D.D. et al. The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int. J. Cancer 55, 630-635 (1993).
16. Nagabuchi, E., VanderKolk, W.E., Une, Y. & Ziegler, M.M. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J. Pediatr. Surg. 32, 287-293 (1997).
17. Duncan, R. et al. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release 74, 135-146 (2001).
18. Rihova, B. et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10, 335-342 (1989).
19. Seymour, L.W., Ulbrich, K., Strohalm, J., Kopecek, J. & Duncan, R. The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39, 1125-1131 (1990).
20. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271-284 (2000).
21. Duncan, R., Coatsworth, J.K. & Burtles, S. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum. Exp. Toxicol. 17, 93-104 (1998).
22. Satchi-Fainaro, R. Targeting tumour vasculature: Reality or a dream? J. Drug Targeting 10, 529-533 (2002).
23. Gianasi, E. et al. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer 35, 994-1002 (1999).
24. Moulton, K.S. et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc. Natl. Acad. Sci. USA 100, 4736-4741 (2003).
25. Greene, A.K. et al. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann. Surg. 237, 530-535 (2003).
26. Whalen, C.T., Hanson, G.D., Putzer, K.J., Mayer, M.D. & Mulford, D.J. Assay of TNP-470 and its two major metabolites in human plasma by high-performance liquid chromatography-mass spectrometry. J. Chromatogr. Sci. 40, 214-218 (2002).
27. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347-360 (2003).
28. Seymour, L.W. et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70, 636-641 (1994).
29. Vasey, P.A. et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5, 83-94 (1999).
30. Dvorak, H.F., Nagy, J.A., Dvorak, J.T. & Dvorak, A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95-109 (1988).
31. Duncan, R., Cable, H.C., Lloyd, J. B., Rejmanova, P. & Kopecek, J. Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side chain in poly N-(2-hydroxypropyl)methacrylamide copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184, 1997-2008 (1984).
32. Foekens, J.A. et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol. 16, 1013-1021 (1998).
33. Strojnik, T., Kos, J., Zidanik, B., Golouh, R. & Lah, T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res. 5, 559-567 (1999).
34. Lah, T.T. et al. Cells producing cathepsins D. B. and L in human breast carcinoma and their association with prognosis. Hum. Pathol. 31, 149-160 (2000).
35. Strojnik, T. et al. Cathepsin B and its inhibitor stefin A in brain tumors. Pflugers Arch. 439, R122-R123 (2000).
36. Griffith, E.C. et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4, 461-471 (1997).
37. Yeh, J.R., Mohan, R. & Crews, C.M. The antiangiogenic agent TNP-470 requires p53 and p21 CIP/WAF for endothelial cell growth arrest. Proc. Natl. Acad. Sci. USA 97, 12782-12787 (2000).
38. Zhang, Y., Griffith, E.C., Sage, J., Jacks, T. & Liu, J.O. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 WAF1/CIP1. Proc. Natl. Acad. Sci. USA 97, 6427-6432 (2000).
39. Duncan, R., Cable, H.C., Strohalm, J. & Kopecek, J. Pinocytic capture and exocytosis of rat immunoglobulin IgG-N-(2-hydroxypropyl)methacrylamide copolymer conjugates by rat visceral yolk sacs cultured in vitro. Biosci. Rep. 6, 869-877 (1986).
40. Seymour, L.W. et al. N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br. J. Cancer 63, 859-866 (1991).
41. Francis, G.E., Delgado, C. & Fisher, D. PEG-modified proteins. in Stability of proteins pharmaceuticals (Part B) (eds. Ahem, T.J. & Manning, M.C.) 235-263 (Plenum Press, New York, 1992).
42. Satchi-Fainaro, R. et al. PDEPT: polymer directed enzyme prodrug therapy II. HPMA copolymer-β-lactamase and HPMA-C-Dox as a second model combination. Bioconjug. Chem. 14, 797-804 (2003).
43. Satchi, R., Connors, T.A. & Duncan, R. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85, 1070-1076 (2001).
44. O'Reilly, M.S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994).
45. Folkman, J., Haudenschild, C.C. & Zetter, B.R. Long-term culture of capillary endothelial cells. Proc. Natl. Acad. Sci. USA 76, 5217-5221 (1979).
46. Auerbach, R., Lewis, R., Shinners, B., Kubai, L. & Akhtar, N. Angiogenesis assays: a critical overview. Clin. Chem. 49, 32-40 (2003).
47. Paxinos, G. & Franklin, K.B.J. The Mouse Brain in Stereotaxic Coordinates (Academic Press, San Diego, 2001).
48. Waynforth, H.B. Routes and methods of administration, intracerebral injection. in Experimental and Surgical Technique in the Rat vol. 2.9; 34-36 (Academic Press, London, 1980).
49. Ong, V.S., Stamm, G.E., Menacherry, S. & Chu, S. Quantitation of TNP-470 and its metabolites in human plasma: sample handling, assay performance and stability. J. Chromatogr. B Biomed. Sci. Appl. 710, 173-182 (1998).